Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, Parikh DP, Heading H, Patel HB, Gupta RJ, Shah CY, Patel MR, Dholakia VN, Sukhadiya R, Jain MR, Parmar KV, Barot K.
Kansagra KA, et al. Among authors: lickliter j.
Clin Pharmacokinet. 2018 Jan;57(1):87-102. doi: 10.1007/s40262-017-0551-3.
Clin Pharmacokinet. 2018.
PMID: 28508936
Free PMC article.
Clinical Trial.